240 related articles for article (PubMed ID: 16520821)
1. Target selectivity in mRNA silencing.
Aronin N
Gene Ther; 2006 Mar; 13(6):509-16. PubMed ID: 16520821
[TBL] [Abstract][Full Text] [Related]
2. RNA-based drugs: from RNA interference to short interfering RNAs.
Poliseno L; Mercatanti A; Citti L; Rainaldi G
Curr Pharm Biotechnol; 2004 Aug; 5(4):361-8. PubMed ID: 15320767
[TBL] [Abstract][Full Text] [Related]
3. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing.
Chakraborty C
Curr Drug Targets; 2007 Mar; 8(3):469-82. PubMed ID: 17348839
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of siRNA-mediated transcriptional gene silencing.
Morris KV
Biotechniques; 2006 Apr; Suppl():7-13. PubMed ID: 16629382
[TBL] [Abstract][Full Text] [Related]
5. Mammalian RNAi: a practical guide.
Sandy P; Ventura A; Jacks T
Biotechniques; 2005 Aug; 39(2):215-24. PubMed ID: 16116795
[TBL] [Abstract][Full Text] [Related]
6. Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.
Fiszer A; Ellison-Klimontowicz ME; Krzyzosiak WJ
Acta Biochim Pol; 2016; 63(4):759-764. PubMed ID: 27770571
[TBL] [Abstract][Full Text] [Related]
7. Oncogene suppression by small interfering RNAs.
Heidenreich O
Curr Pharm Biotechnol; 2004 Aug; 5(4):349-54. PubMed ID: 15320765
[TBL] [Abstract][Full Text] [Related]
8. RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases.
Gaur RK
Biotechniques; 2006 Apr; Suppl():15-22. PubMed ID: 16629383
[TBL] [Abstract][Full Text] [Related]
9. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
10. The diversity of RNAi and its applications.
Gaur RK; Rossi JJ
Biotechniques; 2006 Apr; Suppl():4-5. PubMed ID: 16629381
[No Abstract] [Full Text] [Related]
11. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
De Paula D; Bentley MV; Mahato RI
RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
[TBL] [Abstract][Full Text] [Related]
12. Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer.
Murmann AE; Yu J; Opal P; Peter ME
Trends Cancer; 2018 Oct; 4(10):684-700. PubMed ID: 30292352
[TBL] [Abstract][Full Text] [Related]
13. Recent applications of RNAi in mammalian systems.
Scherer L; Rossi JJ
Curr Pharm Biotechnol; 2004 Aug; 5(4):355-60. PubMed ID: 15320766
[TBL] [Abstract][Full Text] [Related]
14. Designing siRNA that distinguish between genes that differ by a single nucleotide.
Schwarz DS; Ding H; Kennington L; Moore JT; Schelter J; Burchard J; Linsley PS; Aronin N; Xu Z; Zamore PD
PLoS Genet; 2006 Sep; 2(9):e140. PubMed ID: 16965178
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling reveals off-target gene regulation by RNAi.
Jackson AL; Bartz SR; Schelter J; Kobayashi SV; Burchard J; Mao M; Li B; Cavet G; Linsley PS
Nat Biotechnol; 2003 Jun; 21(6):635-7. PubMed ID: 12754523
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
Cambon K; Déglon N
Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
[TBL] [Abstract][Full Text] [Related]
17. The siRNA Non-seed Region and Its Target Sequences Are Auxiliary Determinants of Off-Target Effects.
Kamola PJ; Nakano Y; Takahashi T; Wilson PA; Ui-Tei K
PLoS Comput Biol; 2015 Dec; 11(12):e1004656. PubMed ID: 26657993
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene.
Zhou XM; Lin JS; Shi Y; Tian DA; Huang HJ; Zhou HJ; Jin YX
Acta Biochim Biophys Sin (Shanghai); 2005 May; 37(5):310-6. PubMed ID: 15880259
[TBL] [Abstract][Full Text] [Related]
19. Selective silencing of a mutant transthyretin allele by small interfering RNAs.
Kurosawa T; Igarashi S; Nishizawa M; Onodera O
Biochem Biophys Res Commun; 2005 Nov; 337(3):1012-8. PubMed ID: 16225852
[TBL] [Abstract][Full Text] [Related]
20. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.
Lombardi MS; Jaspers L; Spronkmans C; Gellera C; Taroni F; Di Maria E; Donato SD; Kaemmerer WF
Exp Neurol; 2009 Jun; 217(2):312-9. PubMed ID: 19289118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
